

DCVMN 18th ANNUAL GENERAL MEETING

POLIO VACCINES MANUFACTURERS PERSPECTIVES

Dr. M.Rahman Roestan
Bio Farma



www.biofarma.co.id



YouTube



biofarmaID



Commitment to eradicate polio globally
Support the Program of Global Polio Eradication Initiative

Switch tOPV to bOPV and IPV

sIPV Update

Short Term : Imported Final Products &
Technology Transfer for Formulation Process

Long Term : R&D Collaboration &
Scale up Production




www.biofarma.co.id



biofarmaID



bOPV vaccine supply





www.biofarma.co.id



biofarmaID

Polio Bulk Supply 2012 - 2016



Sustained Supply of Affordable bOPV 2018 – 2021

For routine immunization and Supplementary Immunization Activities (SIA)
Support Polio Eradication and Endgame Strategic Plan

Year	SIA (Qty.in ds.)	RI (Qty. in ds.)	Total SIA & RI (ds.)	Potential buffer (ds.) ^P	Total SIA+RI+buffer (ds.)
2018	682,115,000	260,000,000	942,115,000	200,000,000	1,142,115,000
2019	682,115,000	260,000,000	942,115,000	200,000,000	1,142,115,000
2020	402,115,000	260,000,000	662,115,000	200,000,000	862,115,000
2021	582,960,000	130,000,000	712,960,000	200,000,000	912,960,000





Security stock for outbreak response

Work with the GPEI on establishing a bulk stockpile of mOPV2.
Engage in stockpiling of mOPV2 in case of outbreak

Containment Type 2 Polio Virus :

Upgrade Viral QC Lab & New Lab

Biosafety and Biosecurity System

Assessment of Polio Essential Facilities by NAC



www.biofarma.co.id



biofarmaID

Thank you!



www.biofarma.co.id



biofarmaID